Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tulieve is a veterinary injectable solution containing tulathromycin, a semi-synthetic macrolide antibiotic. It is indicated for the treatment and metaphylaxis of respiratory diseases in cattle (bovine respiratory disease, BRD), pigs (swine respiratory disease, SRD), and sheep (early stages of foot rot). In cattle, it also treats infectious bovine keratoconjunctivitis (IBK). Tulathromycin acts by inhibiting bacterial protein synthesis through binding to the 50S ribosomal subunit, providing bacteriostatic activity against both Gram-positive and Gram-negative pathogens. Tulieve is administered as a single low-volume dose and is rapidly absorbed with long-acting effects. It serves as a generic alternative to Draxxin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tulieve.